1[1]Miwa H, Beran M, Saunder GF. Expession of the Wilms′ tumor gene (WT1) in human leukemias. Leukemia, 1992,6:405-409
2[2]Inoue K, Sugiyama H, Ogama H, et al. WT1 as a new prognostic factor and new marker for the detection of minimal residual disease in acute leukemia. Blood, 1994,84:3071～3079
3[3]Menssen HD, Renkl H J, Rodeck U, et al. Presence of the the Wilms′ tumor gene WT1 transcript and WT1 nuclear protein in the majority of human acute leukemia. Leukemia, 1995,9:1060～1067
4[4]Inoue, K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms′ tumor gene (WT1) in human leukemia. Blood, 1997,89:1405～1412
5[5]Bergmann L, Miething C, Maurer U, et al. High levels of Wilms′ tumor gene (WT1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood, 1997,90:1217～1225
6[6]Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up minimal residual disease in leukemia patients by monitoring WT1 (Wilms′ Tumor Gene) expression levels. Blood, 1996,88:2267～2278
7[7]Ogawa H, Tsuboi A, Oji Y, et al. Successful donor leukocyte transfusion at molecular relapse for a patient with AML who are treated with Allo-BMT: importance of the monitoring of MRD by WT1 assay. BMT, 1998,25:525～562
8[8]Tamaki H, Ogama H, Ohyashiki K, et al. The Wilms′ tumor gene WT1 is a good marker for diagnosis of disease progression of MDS. Leukemia, 1999,13:393～399
9[9]Menssen HD, Renkl HJ, Rodeck U, et al. Detection by monoclonal antibodies of the WT1 nuclear protein in patients with acute leukemias. Int J Cancer, 1997,70:518～523
10[10]Ohninami H, Yasukawa M, Fuji S, et al. HLA class-I restricted of leukemic cells by a CD8+ cytotoxic T-lymphocyte clone specific for WTI peptide. Blood,2000,95:286～293
